Clinical diagnostics · in development

Tests that predict therapy failure before treatment starts.

Over 6.4M cancer diagnoses per year have no molecular biomarkers, leading patients to receive treatments that are ineffective for their disease or associated with debilitating side effects.

Our diagnostics predict patient responses to standard-of-care therapy before treatments start, flagging patients at risk of therapy failure so they can be escalated to more effective alternatives without losing time.

Follow the evidence

A routine IHC tissue section, with a tissue classification map and then a biomarker heatmap drawn over it — An illustrative render of a routine IHC section, first raw, then with a tissue classification map, then with a biomarker heatmap over the tumour regions.

An illustrative render of a routine IHC section, first raw, then with a tissue classification map, then with a biomarker heatmap over the tumour regions.

Lead indication · clinical validation

Head and neck cancer

900,000 diagnoses a year and no molecular diagnostics to guide stratification. Proof of concept published in Cell; validated across three clinics in two countries; patent pending; clinical validation partners engaged in the US and Europe.

POC 1,200patients

Follow-on · evidence building

Colorectal cancer

Third most common cancer worldwide. Proof of concept under review; patent pending.

Horizon · research

Pan-cancer immunotherapy

Checkpoint-response prediction across solid tumours. Our next research angle on the same engine.

Actionable insights, frictionless adoption in any digital pathology lab

Already in every pathology lab

The patient pathway begins as usual.

An FFPE block from a resection or diagnostic biopsy enters the established pathology process. No additional procedures are required from the patient.

MaterialFFPE tissue Patient impactNo additional procedure Change for the labNone

Already in every pathology lab

A familiar stain carries a new signal.

The assay uses standard IHC chemistry and a MultivisionDx staining kit, keeping the wet-lab process close to established routine practice.

MethodRoutine IHC SupplyMVDx staining kit Change for the labMinimal

Already in every digitised lab

No new hardware investments.

The stained slide is digitised with the scanner the lab already operates. The workflow does not depend on a proprietary imaging instrument.

InputWhole-slide image HardwareExisting scanner Change for the labNone

Added by MultivisionDx

Automated spatial profiling of tumour and microenvironment

Tumour, immune environment and spatial architecture are integrated into one interpretable signal and reported through the lab's existing digital workflow.

InputStandard slide scan Platform integrationEstablished digital pathology platforms Change for the labNew analysis module in existing software interface

Added by MultivisionDx

Novel biology; actionable insight

The software generates a prognostic class, patient-specific risk score and predicted therapy response, and the biological reasons behind them.

OutputClinical report Decision supportTherapy benefit DestinationExisting pathology workflow

Diagnostic tests are not yet available for clinical use.

Bring us your dataset, or your biomarker.

The Decode early release is free to test. Thirty minutes is enough to get you set up, or to see whether your discovery has a route to the clinic.

Book a demo